Celltrion Pharm, Inc.

KOSDAQ 068760.KQ

Celltrion Pharm, Inc. Free Cash Flow for the year ending December 31, 2023: USD -3.90 M

Celltrion Pharm, Inc. Free Cash Flow is USD -3.90 M for the year ending December 31, 2023, a 68.14% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Celltrion Pharm, Inc. Free Cash Flow for the year ending December 31, 2022 was USD -12.26 M, a -119.45% change year over year.
Celltrion Pharm, Inc. Free Cash Flow for the year ending December 31, 2021 was USD 63.00 M, a 603.02% change year over year.
Celltrion Pharm, Inc. Free Cash Flow for the year ending December 31, 2020 was USD -12.53 M, a -43.77% change year over year.
Celltrion Pharm, Inc. Free Cash Flow for the year ending December 31, 2019 was USD -8.71 M, a -1,464.89% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

KOSDAQ: 068760.KQ

Celltrion Pharm, Inc.

CEO	Jung-su Seo
IPO Date	Feb. 3, 2006
Location	South Korea
Headquarters	82, 2sandan-ro
Employees	888
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea.

Key trends

Past 5 years